In the News
Business Wire - May 6, 2021
TwinStrand Biosciences Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and Accuracy
TwinStrand’s transformational improvements in DNA sequencing accuracy deliver 10,000x greater sensitivity, making it a crucial tool for genomic research and medicine. Financing was led by Section 32 partner Michael Pellini, MD who has also joined the company’s Board of Directors.
X
TwinStrand Biosciences Announces $50 Million Series B to Expand the Adoption of its Duplex Sequencing Technology in Applications Requiring the Highest Sensitivity and Accuracy
GenomeWeb - January 6, 2021
TwinStrand Biosciences Explores Error Reduction Sequencing Tech in Various Applications
PRNewswire - January 6, 2021
TwinStrand Biosciences Appoints Dr. Gary Gilliland to Board of Directors
PRNewswire - November 18, 2020
TwinStrand Biosciences Licenses Duplex Sequencing Technology to Foundation Medicine
Puget Sound Business Journal - October 1, 2020
40 Under 40: Jesse Salk diagnoses cancer using DNA sequencing and treats the disease as a practicing oncologist
GEN - August 1, 2020
Liquid Biopsies Generate Ample Insights from Sparse Clues
Gene Online - July 20, 2020
The Profound Impact of Duplex Sequencing: An Interview with Jesse Salk, CEO, TwinStrand Biosciences
Bio-IT World - July 15, 2020
In The Midst Of A Pandemic, Duplex Sequencing Comes Of Age
Timmerman Report - June 15, 2020
Timmerman Report- DNA Sequencing Startups Aim to Reduce Cost, Increase Meaning in the Data
GEN - April 1, 2020
Sequencing’s Stars Urge Exploration of New Dimensions
GEN - March 1, 2020
Genomic Medicine Identifies Reconcilable Differences
DeciBio - February 27, 2020
AGBT 2020: DeciBio Highlights – Spatial Profiling Reloaded & MGI Unleashed 2
PRNewswire - February 25, 2020
TwinStrand Biosciences Launches Duplex Sequencing Technology
LinkedIn - January 7, 2020
Leveraging big data to improve genome sequencing accuracy by 10,000x
